CAS: 304909-07-7; N-(4-Benzylpiperazin-1-yl)-1-(3,5-Dimethyl-1-Phenyl-1H-Pyrazol-4-yl)Methanimine
该化合物是化学化合物,其结构复杂,包括一个管子动物和配阳球环.该化合物通常具有与其功能组有关的特性,例如,由于存在以其在医药化学中的角色而闻名的管子和丙基苯基甲醇的潜在生物活动.苯基组可以增强脂性,可能影响到化合物的溶性性和易渗透性.二甲基和苯基子分组的存在可能会影响其再活动以及与生物目标的相互作用.作为合成有机化合物,它可能有兴趣进行药理学研究,特别是开发新的治疗剂.然而,熔点,沸点和溶性等具体物理特性需要实验性测量或文献参考,以得出准确值.安全及处理考虑的因素,如任何化学物质一样,也应予以考虑.
- 英文名称N-(4-Benzylpiperazin-1-yl)-1-(3,5-Dimethyl-1-Phenyl-1H-Pyrazol-4-yl)Methanimine
- 中文名称(E)-N-(4-苄基-1-哌嗪基)-1-(3,5-二甲基-1-苯基-1H-吡唑-4-基)甲亚胺
- IUPAC名称(E)-N-(4-benzylpiperazin-1-yl)-1-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methanimine
- 其它别名Quiral Tadeodal; Sant-1; (E)-4-Benzyl-N-((3,5-Dimethyl-1-Phenyl-1H-Pyrazol-4-yl)Methylene)Piperazin-1-Amine; (4-Benzyl-Piperazin-1-yl)-(3,5-Dimethyl-1-Phenyl-1H-Pyra
- CAS编号304909-07-7
- MFCD编号:MFCD01827306
- FDA UNII编号:GYK6BKF2M2
- 分子式:C23H27N5分子量:373.5
- 产品CID: 1290568
- 产品分类生物化工 → 抑制剂 → 干细胞及Wnt信号通路（Stem Cells 和 Wnt） → 刺猬/光滑蛋白拮抗剂
物理性质
- 熔点104-106°C
- 沸点547.4±50.0 °C(预测)
- 闪点284.8 °C
- 密度1.13±0.1 g/cm3(预测)
- pKa:7.35±0.10(预测)
- PSA:36.66
- LogP:3.5166
- 折射率1.62
- 蒸汽压0 mmHg at 25 °C
- 溶解性Soluble In DMSO With Warming
- 敏感性吸潮 & 光敏感
- 外观形态白色至类白色白色固体
- 储存条件-20°C
- 产品应用该化合物是一种与SMO直接结合的强力滑动(SMO)受体抗体抗应剂,其KD为1.2纳米的KD,它抑制了20纳米的IC50的SMO亚效活性;它有效地抑制了野型和诱诱性SMO在体外体内的活动;它使SAG诱导的SMO途径在 SHUSH-LIGHT2 细胞中激活产生对抗;抑制BODIPY-环氧胺与SMO 表达细胞结合,暗示了一种过敏调节而不是直接的竞争约束;块SAG的中间途径激活,其效力很高;抑制环球胺和由JERVINE引起的SMO迁移到主要硅;抑制PKA刺激SMO贩运到准氧化硅;以及与HDAC抑制剂SAHA一道抑制了红细胞扩散和聚积聚体在抗宝石抗体的聚癌细胞癌细胞细胞细胞系列PANC-1和BXPC-3的形成.
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2902300000-甲苯
2921211000-乙二胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9662347-B2
优先权日:2010-05-11
标题 :Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
发明人：LEE BONG HEE; BYUN KYUNG HEE
权利人:LEE BONG HEE; BYUN KYUNG HEE; GACHON UNIV OF INDUSTRY-ACADEMIC COOP FOUND
摘要:The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death. Therefore, the AGE-albumin synthesis inhibitor of the present invention can be valuably used in the diagnosis or treatment of degenerative diseases or autoimmune diseases such as Alzheimer's disease, strokes, Parkinson's disease, amyotrophic lateral sclerosis, rheumatoid arthritis, diabetic retinopathy, AIDS, aging, pulmonary fibrosis, spinal cord injuries, etc.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
参考文献:10.1371/journal.pone.0218897
摘要:Miller TW, Amason JD, Garcin ED, Lamy L, Dranchak PK, Macarthur R, Braisted J, Rubin JS, Burgess TL, Farrell CL, Roberts DD, Inglese J. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. PLoS ONE. 2019 Jul 05;14(7):e0218897. doi: 10.1371/journal.pone.0218897.
📝 需求与反馈
尽可能描述清楚需求与问题信息
